SK-UT-1B ve Ishikawa Kanser Hücre Hatlarında Papainin Antikanser Etkilerinin Belirlenmesi

Öz

Amaç: Endometriyal kanser en yaygın jinekolojik malignite olup, dünya genelinde kadınlarda en sık görülen altıncı kanserdir. Bu çalışmada, alternatif bir yaklaşım olarak Carica papaya'dan elde edilen proteolitik bir enzim olan papainin SK-UT-1B (insan uterus leiomyosarkomu) ve Ishikawa (insan endometriyal adenokarsinomu) hücre hatları üzerindeki etkilerinin değerlendirilmesi amaçlanmıştır. Metod: Papainin 10 ila 100 µM arasında değişen konsantrasyonlarda hücre canlılığı üzerindeki etkisi SK-UT-1B ve Ishikawa hücrelerinde 3-(4,5-dimetiltiyazol-2-il)-2,5- difeniltetrazolyum bromür (MTT) testi ile değerlendirilmiştir. Ayrıca, papainin anti-kanser etkilerini belirlemek amacıyla hücrelerde immünofloresan boyama kullanılarak immünolojik ve anjiyojenik özelikleri olan IL-13 ve VEGF-A ekspresyonunu değerlendirmek amacıyla immunositokimyasal analizler yapılmıştır. Sonuçlar: Papain, 20 µM üzerindeki konsantrasyonlarda hücre canlılığını azaltarak doza bağlı antiproliferatif etkiler sergilemiştir. SK-UT-1B hücreleri için papainin IC50 (the half-maximal inhibitory concentration) değeri 54.774 µM; Ishikawa hücreleri için IC50 değeri 43.982 µM olarak bulunmuştur. Her iki hücre hattı için düşük, orta ve yüksek doz olarak 20, 40, 60 µM dozları belirlenmiş; IL-13 ve VEGF-A konsantrasyonları tedavi edilen hücrelerde doza bağlı olarak önemli ölçüde azalmıştır. Sonuç: Papain hücre canlılığını inhibe etmiş ve anti-kanser ajan olarak potansiyelini ortaya koymuştur. Bu bulguları doğrulamak ve papainin kanser tedavisindeki terapötik uygulamalarını keşfetmek için daha fazla in vivo ve in vitro çalışmaya ihtiyaç vardır.

Anahtar Kelimeler

• Papain
• anti-kanser etkiler
• endometrium kanseri

Determination of the Anticancer Effects of Papain in SK-UT-1B and Ishikawa Cancer Cell Lines

Abstract

Aim: Endometrial cancer is the most common gynecologic malignancy and ranks sixth among cancers in women worldwide. Papain is a cysteine protease derived from Carica papaya, known for its antinflammatory, antimicrobial, and potential anticancer properties. This study aimed to investigate the effects of papain on SK-UT-1B (uterine leiomyosarcoma) and Ishikawa (endometrial adenocarcinoma) cell lines. Material and Methods: SK-UT-1B and Ishikawa cells were treated with papain at concentrations ranging from 10 to 100 µM. Cell viability was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Immunofluorescent staining was performed to examine the expression of IL-13 and VEGF-A. Results: Papain exhibited dose-dependent antiproliferative effects by reducing cell viability at concentrations above 20 µM. The IC50 (the half-maximal inhibitory concentration) value of papain was 54.774 µM for SK-UT-1B cells and 43.982 µM for Ishikawa cells. Low, medium and high doses of 20, 40, 60 µM were determined for both cell lines; IL-13 and VEGF-A concentrations decreased significantly in the treated cells in a dose-dependent manner. Conclusions: These findings suggest that papain exerts antiproliferative and antiangiogenic effects in endometrial cancer cells by reducing cell viability and downregulating IL-13 and VEGF-A expression, supporting its potential as a promising anticancer candidate. Keywords: Papain, anti- cancer effects, endometrial cancer

Keywords

• Papain
• anti- cancer effects
• endometrial cancer

Kaynakça

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018;68(6), 394–424. doi.org/10.3322/caac.21492
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 2023;73(1), 17–48. doi.org/10.3322/caac.21763
3. Colombo N, Creutzberg C, Amant F, et al. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2016;27(1), 16–41. doi.org/10.1093/annonc/mdv484
4. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: Have they different risk factors?. Journal of Clinical Oncology. 2013;31(20), 2607–2618. doi.org/10.1200/JCO.2012.48.2596
5. Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Advances in Experimental Medicine and Biology. 2017;943:3-46. doi: 10.1007/978-3-319-43139-0_1
6. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021;31(1), 12–39. doi.org/10.1136/ijgc-2020-002230
7. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 2020;83(3), 770–803. doi.org/10.1021/acs.jnatprod.9b01285
8. Iqbal MJ, Kabeer A, Abbas Z, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Communication and Signaling. 2024;22(1), 7. doi: 10.1186/s12964-023-01398-5

9. Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy, 2024;9(1), 176. doi: 10.1038/s41392-024-01868-3
10. Silva CR, Oliveira MBN, Motta ES, et al. Genotoxic and cytotoxic safety evaluation of papain (Carica papaya L.) using in vitro assays. BioMed Research International. 2010;2010(1), 197898. doi: 10.1155/2010/197898
11. Babalola BA, Akinwande AI, Otunba AA, Adebami GE, Babalola O, Nwufo C. Therapeutic benefits of Carica papaya: A review on its pharmacological activities and characterization of papain. Arabian Journal of Chemistry, 2024;17(1). doi.org/10.1016/j.arabjc.2023.105369
12. Kumar NS, Devi PSS. The surprising health benefits of papaya seeds: A. J. Pharmacogn. Phytochem. 2017;6(1), 424-429.
13. Li T, Yan G, Bai Y, et al. Papain bioinspired gold nanoparticles augmented the anticancer potency of 5-FU against lung cancer. Journal of Experimental Nanoscience. 2020;15(1), 109-128. doi: 10.1080/17458080.2020.1746767
14. Park NC, Han SJ, Lee JW, et al. Apoptotic effect of Gyejibokryunghwan on uterine sarcoma cells (SK-UT-1B). Phytomedicine. 2019;61, 152806. doi: 10.1016/j.phymed.2018.12.029
15. Holinka CF, Hata H, Kuramoto H, Gurpide E. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). Journal of Steroid Biochemistry, 1986;24(1), 85-89. doi: 10.1016/0022-4731(86)90036-1
16. Zhang Z, Ding Y. MG132-mediated Suppression of the Ubiquitin-proteasome Pathway Enhances the Sensitivity of Endometrial Cancer Cells to Cisplatin. Anti-Cancer Agents in Medicinal Chemistry. 2025;25(4), 281-291. doi: 10.2174/0118715206343550240919055701
17. Berger AA, Dao F, Levine DA. Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives. Gynecologic Oncology, 2021;160(3), 844-850. doi.org/10.1016/j.ygyno.2020.12.016
18. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy. 2021;6(1), 263. doi: 10.1038/s41392-021-00658-5
19. Asif S, Kaur G, Pendurthi U, et al. Papain-mediated reduction of MTT is an artifact but not an indicator of cell apoptosis in Saccharomyces cerevisiae. Journal of Applied Pharmaceutical Science. 2019;9(9), 119-124. doi: 10.7324/JAPS.2019.90917
20. Müller A, Barat S, Chen X, et al. Comparative study of antitumor effects of bromelain and papain in human cholangiocarcinoma cell lines. International Journal of Oncology. 2016;48(5), 2025-2034. doi: 10.3892/ijo.2016.3411
21. de Lima CSA, Rial-Hermida MI, de Freitas LF, et al. Mucoadhesive gellan gum-based and carboxymethyl cellulose-based hydrogels containing gemcitabine and papain for bladder cancer treatment. International Journal of Biological Macromolecules. 2023;242, 124957. doi: 10.1016/j.ijbiomac.2023.124957
22. Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. International Journal of Molecular Sciences. 2021;22(6), 2998. doi: 10.3390/ijms22062998
23. Zhang Y, Zhu K, Wang X, Zhao Y, Shi J, Liu Z. Roles of IL-4, IL-13, and their receptors in lung cancer. Journal of Interferon & Cytokine Research. 2024;44(9), 399-407. doi: 10.1089/jir.2024.0008
24. Melo-Cardenas J, Bezavada L, Crawford JC, et al. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood, The Journal of the American Society of Hematology. 2022;140(26), 2805-2817. doi: 10.1182/blood.2022017326
25. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Research. 2012;72(24), 6338-6343. doi: 10.1158/0008-5472.CAN-12-3544
26. Kimura G, Tagami A, Fukui R, Yaita M, Miyasaka T. Airway inflammation in a novel mouse model of asthma-COPD overlap induced by co-exposure to papain and tobacco smoke. Biochemical and Biophysical Research Communications. 2024;709, 149831. doi: 10.1016/j.bbrc.2024.149831
27. Wang Z, Yan C, Du Q, et al. HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation. Cellular & Molecular Immunology. 2023;20(4), 404-418. doi: 10.1038/s41423-023-00982-6
28. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biology. 2015;44, 94-112. doi: 10.1016/j.matbio.2015.04.004
29. Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2), 455-467.
30. Lin Y, Zhai E, Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. Oncotarget. 2017;8(7), 11990. doi: 10.18632/oncotarget.14467
31. Kras P, Talkowski K, Grabarek BO, Skalska-Dziobek N, Boroń D, Oplawski M. Evaluation of Variances in VEGF-AD and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect. Current Pharmaceutical Biotechnology. 2021;22(5), 697-705. doi: 10.2174/1389201021666200710093519
32. Fiordi B, Salvestrini V, Gugliotta G, et al. IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia. Haematologica. 2023;108(9), 2396. doi: 10.3324/haematol.2022.282140